Viatris Inc.

Viatris Inc. is a global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania, with additional global centers in Pittsburgh, Shanghai, and Hyderabad. Formed on November 16, 2020, through the merger of Mylan and Upjohn, a legacy division of Pfizer, its mission is to empower people worldwide to live healthier at every stage of life. This mission is rooted in expanding access to medicines, innovating to meet patient needs, and serving as a trusted partner for the global healthcare community.

The company offers a diverse portfolio of medicines, including branded drugs, generics (both branded and complex), biosimilars, over-the-counter products, and active pharmaceutical ingredients. Viatris products address a broad range of therapeutic areas such as cardiovascular, infectious disease, oncology, immunology, CNS and anesthesia, women's healthcare, diabetes and metabolism, gastroenterology, respiratory and allergy, and dermatology. Serving patients across various demographics, healthcare providers, pharmacies, and governments, Viatris operates in over 165 countries, focusing on both developed and emerging markets.

Scott A. Smith has served as CEO since April 2023. Viatris positions itself as a leader in global healthcare access, aiming to bridge the gap between generic and branded pharmaceutical offerings while advancing sustainable operations. The company is strategically expanding its pipeline, with a focus on complex generics, biosimilars, and specialty areas like ophthalmology, dermatology, and gastroenterology. Recent developments include presenting data on an investigational low-dose estrogen combined hormonal contraceptive weekly patch in May 2026, with an FDA target action date of July 30, 2026. In March 2026, Japan approved Effexor SR capsules for generalized anxiety disorder. The company also launched Inpefa® (Sotagliflozin) for heart failure in January 2026. Notably, Viatris disclosed an FDA warning letter and import alert concerning its Indore, India facility in late December 2024, impacting 11 products. This followed strategic divestitures in October 2023 of its OTC, women's healthcare, and India-based API businesses, totaling approximately $3.6 billion.

Latest updates

Viatris Presents Data on Low-Dose Contraceptive Patch Ahead of FDA Decision

Event summary

  • Viatris will present six abstracts at the 2026 ACOG Annual Clinical & Scientific Meeting related to its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly patch.
  • Data presented includes results from a Phase 3 study (NCT05139121) demonstrating contraceptive efficacy and safety, as well as adhesion profile, pharmacokinetic data, and cycle control data.
  • The FDA has assigned a target action date of July 30, 2026, for the NDA submitted under the 505(b)(2) regulatory pathway.
  • Viatris provided an independent educational grant for a symposium hosted by PRIME focused on non-oral contraceptive options.

The big picture

Viatris is attempting to expand its contraceptive portfolio with a lower-dose patch, leveraging its existing transdermal drug delivery expertise. The 505(b)(2) pathway suggests a reliance on existing data, potentially accelerating approval but also limiting exclusivity. The success of this product will be a key test of Viatris’s ability to innovate within a mature market and compete with established players.

What we're watching

Regulatory Risk
The FDA’s assessment of the presented data will be critical; a negative review could delay or deny approval, impacting Viatris’s projected revenue.
Market Adoption
The success of the patch will depend on physician and patient acceptance, which will be influenced by the presented data on adhesion and cycle control.
Competitive Landscape
Viatris will need to demonstrate a clear advantage over existing contraceptive options, including Xulane, to achieve significant market share.
CID: 893